Canadian Humira Post Marketing Observational Epidemiological Study Assessing Effectiveness in Psoriatic Arthritis (Complete-PsA)

Trial Profile

Canadian Humira Post Marketing Observational Epidemiological Study Assessing Effectiveness in Psoriatic Arthritis (Complete-PsA)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 06 Aug 2018

At a glance

  • Drugs Adalimumab (Primary) ; Disease-modifying antirheumatics
  • Indications Psoriatic arthritis
  • Focus Therapeutic Use
  • Acronyms COMPLETE- PsA
  • Sponsors Abbott Canada; AbbVie
  • Most Recent Events

    • 16 Jun 2018 Results (as of Jun 2016; n=406; 12-month effectiveness data) presented at the 19th Annual Congress of the European League Against Rheumatism.
    • 28 Dec 2017 Status changed from recruiting to active, no longer recruiting.
    • 17 Jul 2017 Planned End Date changed from 1 Jun 2020 to 30 Nov 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top